Fracture risk assessment without bone density measurement in routine clinical practice

Assessing the Value of Risk Predictions by Using Risk Stratification Tables

(2013) Holly Janes et al.   ANNALS OF INTERNAL MEDICINE

A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®

(2011) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Erratum to: A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®

(2011) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX®

(2010) John A. Kanis et al.   BONE

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

(2010) A. Papaioannou et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US national osteoporosis foundation guidelines

(2010) Meghan G Donaldson et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration

(2010) William D Leslie et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos

(2010) L.-A. Fraser et al.   OSTEOPOROSIS INTERNATIONAL

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®

(2009) John A. Kanis et al.   BONE

Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study

(2009) S. D. Berry et al.   OSTEOPOROSIS INTERNATIONAL

FRAX® assessment of osteoporotic fracture probability in Switzerland

(2009) K. Lippuner et al.   OSTEOPOROSIS INTERNATIONAL

Estimates of the Proportion of Older White Women Who Would Be Recommended for Pharmacologic Treatment by the New U.S. National Osteoporosis Foundation Guidelines

(2008) Meghan G Donaldson et al.   JOURNAL OF BONE AND MINERAL RESEARCH

A Revised Clinician’s Guide to the Prevention and Treatment of Osteoporosis

(2008) Bess Dawson-Hughes   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States

(2008) J. R. Curtis et al.   OSTEOPOROSIS INTERNATIONAL

Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study

(2008) E. V. McCloskey et al.   OSTEOPOROSIS INTERNATIONAL

Cost-effective osteoporosis treatment thresholds: the United States perspective

(2008) A. N. A. Tosteson et al.   OSTEOPOROSIS INTERNATIONAL

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA

(2008) B. Dawson-Hughes et al.   OSTEOPOROSIS INTERNATIONAL

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

FRAX™ and the assessment of fracture probability in men and women from the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

A reference standard for the description of osteoporosis

(2007) John A. Kanis et al.   BONE